AVBP Stock Analysis: ArriVent BioPharma, Common | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.535m USD | 12M Return: 61.4% | US04272N1028 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.8M
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing oncology therapies for cancers with limited treatment options. Its lead candidate, firmonertinib, is an oral tyrosine kinase inhibitor being studied across multiple non-small cell lung cancer (NSCLC) settings driven by EGFR mutations, including a Phase 3 trial in EGFR exon 20 insertion NSCLC and Phase 1b trials in PACC and classical EGFR-mutated disease. The broader pipeline includes an antibody-drug conjugate (ARR-217) aimed at gastrointestinal cancers and additional early-stage solid tumor programs.
The company, founded in 2021 and headquartered in Newtown Square, Pennsylvania, relies on a partnership-driven model, collaborating with developers such as Shanghai Allist Pharmaceuticals, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, Lepu Biopharma, and Aarvik Therapeutics to access and advance its candidates. As a clinical-stage biotech, ArriVent has no approved products and depends on capital markets and collaboration milestones rather than product sales to fund operations, a typical structure for small-cap oncology developers that went public in early 2024.
- Firmonertinib Phase 3 NSCLC trial data readout
- FDA approval pathway for exon 20 insertion indication
- Cash burn and capital raises pressure clinical-stage valuation
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.37 > 0.02 and ΔFCF/TA 9.51 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -147.9m > Net Income -163.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.6m) vs 12m ago 36.00% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.93 (Total Current Assets 394.2m - Total Current Liabilities 27.8m) / Total Assets 394.7m |
| B: -1.26 (Retained Earnings -497.9m / Total Assets 394.7m) |
| C: -0.53 (EBIT TTM -175.9m / Avg Total Assets 332.1m) |
| D: 13.16 (Book Value of Equity 366.8m / Total Liabilities 27.9m) |
| Altman-Z'' = 12.23 = AAA |
As of August 28, 2026, the stock is trading at USD 31.00 with a total of 299,970 shares traded. Over the past week, the price has changed by +6.24%, over one month by +2.79%, over three months by +12.85% and over the past year by +61.37%.
Current recommended Stop Loss: 26.80 (which is 13.5% or 2.6 ATR below the current price).
ArriVent BioPharma, Common has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy AVBP.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.7 | 44.2% |
P/B = 4.2259
Revenue TTM = 0.0 USD
EBIT TTM = -175.9m USD
EBITDA TTM = -175.9m USD
Long Term Debt = 33.0k USD (estimated: total debt 351k - short term 318k)
Short Term Debt = 318k USD (from shortTermDebt, last quarter)
Debt = 770k USD (from shortLongTermDebtTotal, last quarter) + Leases 419k
Net Debt = -372.3m USD (calculated: Debt 770k - CCE 373.1m)
Enterprise Value = 1.16b USD (1.54b + Debt 770k - CCE 373.1m)
Interest Coverage Ratio = unknown (Ebit TTM -175.9m / Interest Expense TTM 0.0)
EV/FCF = -7.86x (Enterprise Value 1.16b / FCF TTM -147.9m)
FCF Yield = -12.72% (FCF TTM -147.9m / Enterprise Value 1.16b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.95 (Enterprise Value 1.16b / Total Assets 394.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 770k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -139.0m (EBIT -175.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.16 (Total Current Assets 394.2m / Total Current Liabilities 27.8m)
Debt / Equity = 0.00 (Debt 770k / totalStockholderEquity, last quarter 366.8m)
Debt / EBITDA = 2.12 (negative EBITDA) (Net Debt -372.3m / EBITDA -175.9m)
Debt / FCF = 2.52 (negative FCF - burning cash) (Net Debt -372.3m / FCF TTM -147.9m)
Total Stockholder Equity = 325.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.30% (Net Income -163.7m / Total Assets 394.7m)
RoE = -50.26% (Net Income TTM -163.7m / Total Stockholder Equity 325.8m)
RoCE = -54.00% (EBIT -175.9m / Capital Employed (Equity 325.8m + L.T.Debt 33.0k))
RoIC = -37.85% (negative operating profit) (NOPAT -139.0m / Invested Capital 367.2m)
WACC = 8.74% (E(1.54b)/V(1.54b) * Re(8.74%) + D(770k)/V(1.54b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.96 | Cagr: 16.91%
[DCF] Fair Price = unknown (Cash Flow -147.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.15 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.07 | Chg30d=-11.00% | Revisions=-25% | Analysts=9
EPS current Year (2026-12-31): EPS=-4.34 | Chg30d=-7.91% | Revisions=-40% | GrowthEPS=-0.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.81 | Chg30d=-8.76% | Revisions=-50% | GrowthEPS=+12.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -67% (up=0, down=6)